Neurological Institute Outcomes
Headache
Eptinezumab Infusions
Eptinezumab Infusions
2022
GAD-7 = Generalized Anxiety Disorder Questionnaire, HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System.
Eptinezumab is the first anti-CGRP drug to be administered quarterly intravenously. In February 2020, eptinezumab was approved for adult migraine treatment in the USA. In 2022, 213 headache patients were provided eptinezumab treatment and completed at least one follow-up questionnaire following the initiation of treatment. 45% of patients had improved headache impact scores.¹ PROMIS global health,² depression,³ and anxietyâ´ were stable or improved in 90% of patients or more.